Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Type Iγ phosphatidylinositol phosphate kinase regulates PD-L1 expression by activating NF-κB
Xue, Junli , Chen, Chunhua , Qi, Manlong, Wang, Lin , Gao, Yong , Ling, Kun , Huang, Yan , Dong, Haidong

Mayo Clinic

Oncotarget | April 15, 2017 | Volume: 8 | Issue: 26 | Pages: 42414-42427

10.18632/oncotarget.17123 | PMID 28465490 Get It

Cardiac autonomic control and complexity during sleep are preserved after chronic sleep restriction in healthy subjects
Covassin, Naima , Calvin, Andrew D. , Singh, Prachi , Bukartyk, Jan , Wang, Shiang, Montano, Nicola , Tobaldini, Eleonora, Calvin, Andrew, Tobaldini, Eleonora , Wang, Shiang, Somers, Virend K. , Singh, Prachi , Calvin, Andrew D , Montano, Nicola

Mayo Clinic

Physiological Reports | April 13, 2017 | Volume: 5 | Issue: 7 | Pages: e13197

10.14814/phy2.13197 | PMID 28408635 Get It

Association Between Vascular Pathology and Rate of Cognitive Decline Independent of Alzheimer's Disease Pathology
Ezzati, Ali , Wang, Cuiling , Altschul, Dorothea , Katz, Mindy J. , Lipton, Richard B. , Dickson, Dennis W. , Derby, Carol A.

Mayo Clinic

Journal of the American Geriatrics Society | April 13, 2017 | Volume: 65 | Issue: 8 | Pages: 1836-1841

10.1111/jgs.14903 | PMID 28407205 Get It

Objectives To examine the association between vascular pathology and rate of cognitive decline in older adults independent of Alzheimer's disease ( AD ) pathology. Design Prospective cohort study. Setting Community sample. Participants Individuals from the Einstein Aging Study autopsy series (N = 62). Measurements The Blessed Information‐Memory‐Concentration ( BIMC ) test was used to assess global cognitive status. AD pathology was quantified according to Braak stage (<3 vs ≥ 3). Vascular pathology was quantified using a previously reported macrovascular lesion ( MVL ) score. The association between vascular pathology and antemortem rates of cognitive decline adjusted for level of AD pathology was assessed using linear mixed‐effects models. Results Mean age was 81.8 at enrollment and 89.0 at death. Participants with more than two MVL s had faster cognitive decline than those with no MVL s (difference in annual rate of change in BIMC 0.74 points/yr, P = .03). Braak stage was also associated with cognitive decline (difference 0.57 points/yr, P = .03). The difference in rate of cognitive decline between those with more than two MVL s and those free of vascular lesions persisted after adjustment for AD pathology (difference in rate of change in BIMC 0.68 points/yr, P = .04). The effect of vascular pathology on cognitive decline was not significantly different according to AD pathology. Conclusion Vascular brain pathology is associated with rate of cognitive decline after adjusting for level of AD pathology.
Adjunctive Corticosteroid Therapy in the Treatment of Coccidioidal Meningitis
Blair, Janis E. , Wang, Sharon, Bercovitch, Robert, Bolaris, Michael , Akker, Dane Van Den, Heidari, Arash , Catanzaro, Antonino , Chin‐Hong, Peter , Spellberg, Brad , Johnson, Royce H. , Thompson, George R , López, Rodrigo , Cadena, José

Mayo Clinic

Clinical Infectious Diseases | April 10, 2017 | Volume: 65 | Issue: 2 | Pages: 338-341

10.1093/cid/cix318 | PMID 28419259 Get It

Clinical Features of Acquired Resistance to Anti–PD-1 Therapy in Advanced Melanoma
Eroglu, Zeynep , Özgün, Alpaslan, Leger, Paul, Ye, Fei , Luke, Jason J. , Haq, Rizwan , Ott, Patrick A. , Hodi, F. Stephen , Sosman, Jeffrey A. , Johnson, Douglas B. , Buchbinder, Elizabeth I. , Wang, Daniel Y. , Zhao, Shilin , Joseph, Richard W. , Luke, Jason J

Mayo Clinic

Cancer Immunology Research | April 10, 2017 | Volume: 5 | Issue: 5 | Pages: 357-362

10.1158/2326-6066.cir-16-0287 | PMID 28396509 Get It

Abstract Anti–PD-1 therapy has improved clinical outcomes in advanced melanoma, but most patients experience intrinsic resistance. Responding patients can develop acquired resistance to anti–PD-1. We retrospectively reviewed 488 patients treated with anti–PD-1 from three academic centers and identified 36 patients with acquired resistance, defined as disease progression following objective response. The incidence, timing, disease sites, post-progression survival (PPS), and outcomes were evaluated descriptively. The acquired resistance cohort consisted of 67% with more than 1 feature of poor prognosis (stage M1c, elevated LDH, or brain metastasis), and 67% had previously received ipilimumab. Partial and complete responses were achieved in 89% (n = 32) and 11% (n = 4) of patients, respectively, and median time to resistance (progression-free survival; PFS) was 11.1 months (range 4.3–32.8 months). Most progression was isolated (78% of patients, n = 28) and occurred while receiving therapy (78%, n = 28). The median PPS was 12.8 months (range 0.1–51.8 months), and the median overall survival was 33.7 months. Among isolated progressors, 15 received localized therapy (12 with surgery, 3 with radiation). Patients with isolated versus systemic progression exhibited a trend for improved PPS (P = 0.081), and patients with an initial PFS ≥ 15 months showed significant PPS improvement (P = 0.036). Two patients experienced subsequent responses to anti–PD-1 resumption. In conclusion, acquired resistance to anti–PD-1 was frequently associated with excellent clinical outcomes and often presented as isolated progression amenable to localized therapy (surgery or radiation) or systemic progression sensitive to therapy resumption. Cancer Immunol Res; 5(5); 357–62. ©2017 AACR.
Cognitive Performance Correlates with Cortical Isopeptide Immunoreactivity as Well as Alzheimer Type Pathology
Wang, Deng-Shun, Uchikado, Hirotake, Bennett, David A. , Mufson, Elliott J. , Bennett, David A. , Schneider, Julie A. , Wu, Joanne , Dickson, Dennis W.

Mayo Clinic

Journal of Alzheimer's Disease | April 5, 2017 | Volume: 13 | Issue: 1 | Pages: 53-66

10.3233/jad-2008-13106 | PMID 18334757 Get It

Low incidence of treatment-related myelodysplastic syndrome (tMDS) and acute myelogenous leukemia (tAML) in patients with non-Hodgkin's lymphoma (NHL) treated with ibritumomab tiuxetan
Emmanouilides, C., Czuczman, M. S., REVELL, S T, Wang, H. , Skikne, B. , Witzig, Thomas E. , Gordon, Leo I. , Foster, Paul , Molina, Aurelia Alañón

Mayo Clinic

Journal of Clinical Oncology | April 5, 2017 | Volume: 22 | Issue: 14_suppl | Pages: 6696-6696

10.1200/jco.2004.22.90140.6696 Get It

Characterization of fusion genes in common and rare epithelial ovarian cancer histologic subtypes
Earp, Madalene A. , Li, Qian , Cunningham, Julie M. , Natanzon, Yanina , Kalli, Kimberly R., Hou, Xiaonan , Weroha, S. John , Haluska, Paul , Lawrenson, Kate , Gayther, Simon A. , Goode, Ellen L. , Winham, Stacey J. , Raghavan, Rama , Dai, Junqiang , Wang, Chen , Fridley, Brooke L. , Lawrenson, Kate

Mayo Clinic

Oncotarget | April 1, 2017 | Volume: 8 | Issue: 29 | Pages: 46891-46899

10.18632/oncotarget.16781 | PMID 28423358 Get It

EGFR-induced phosphorylation of type Iγ phosphatidylinositol phosphate kinase promotes pancreatic cancer progression
Wang, Xiangling , Fang, Juemin, Xue, Junli , Xiong, Xunhao, Huang, Yan , Hu, Jinghua , Ling, Kun , Chen, Chunhua

Mayo Clinic

Oncotarget | March 31, 2017 | Volume: 8 | Issue: 26 | Pages: 42621-42637

10.18632/oncotarget.16730 | PMID 28388589 Get It